MOONLAKE IMMUNO (MLTX)
(Real Time Quote from BATS)
$45.54 USD
+2.48 (5.76%)
Updated Aug 8, 2024 03:39 PM ET
After-Market: $46.06 +0.52 (1.14%) 4:06 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
MoonLake Immunotherapeutics [MLTX]
Reports for Purchase
Showing records 41 - 60 ( 95 total )
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Hitting the High Bar in HS; 24wk MIRA Data Exceed Expectations
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: MoonLake Immunotherapeutics
Industry: Unclassified
EADV Presentation Reinforces SLK''s Best-in-Class Position; 24wk Data Imminent
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Survey Reveals Investor Expectations Ahead of the 24wk HS 12wk PsA Readouts
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Company: MoonLake Immunotherapeutics
Industry: Unclassified
QUICK Investor Survey Ahead of Ph2 24wk in HS and Ph2 12wk in PsA in Oct, Nov
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: MoonLake Immunotherapeutics
Industry: Unclassified
It Isn''t So for Izo, SLK''s Profile Reinforced in HS; Capital Markets Day Recap
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Sonelokimab Rises Head and Shoulders Above Competition; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Q2: Driving Additional Value with Near-Term De-Risked Ph2 Readouts for SLK
Provider: Wedbush Securities Inc.
Analyst: ARGYRIDES A
Company: MoonLake Immunotherapeutics
Industry: Unclassified
Initial PsA Data and More HS Data in 4Q23; 2Q23 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R